T ype 2 diabetes mellitus (T2D) and cardiovascular disease (CVD) are clinically associated in adults 1 and are an increasing public health and economic scourge in the United States 2,3 and worldwide. 4, 5 Better prevention strategies require comprehension of risk factors and mediators underlying T2D and CVD. 6 T2D and CVD share a common metabolic milieu that triggers metabolic and vascular dysfunction starting at subclinical disease stages 7 because of genetic and nongenetic risk factors. In particular, many recently identified common genetic variants increasing T2D risk also are associated with increased CVD risk 8,9 and so might confer risk for subclinical atherosclerosis (SCA). 10
patients. 8 We have also shown that an additive GRS 62 comprising 62 validated T2D-associated SNPs [11] [12] [13] [14] predicts incident T2D in European and African Americans. 15, 16 The present work sought to investigate whether the T2D genetic burden, as represented by the polygenic T2D GRS 62 , is associated in cross-sectional analyses with variation in SCA measures, including coronary artery (CACS) or abdominal aortic calcium score, internal (ICA-IMT) or common carotid artery intima-media thickness (CCA-IMT), and ankle-brachial index (ABI).
To maximize our sample size, we conducted a multicenter transethnic association study in large population samples from 4 studies currently ongoing across the United States: the Framingham Heart Study (FHS), the Coronary Artery Risk Development in Young Adults (CARDIA), 17 the Multi-Ethnic Study of Atherosclerosis (MESA), 18, 19 and the Genetic Epidemiology Network of Arteriopathy (GENOA). 20, 21 
Methods Population

The Offspring Cohort of the Framingham Heart Study
Analyses were conducted for each measured SCA trait on a range of 1111 ≤2822 participants of European ancestry from the Offspring Cohort of the FHS. 22 These subjects pertained the same cohort used to validate the predictability of incident T2D by GRS 62 . 19 Outcomes of interest and clinical characteristics were obtained at Offspring examination cycles 6 (for analyses of ICA-IMT and CCA-IMT) and 7 (for CACS and abdominal aortic calcium score). ABI was measured between the 2 examinations, and covariates included in ABI analyses were from the closest examination to ABI evaluation date. More details have been published previously. 22, 23 The CARDIA Study Analyses were conducted for the available SCA traits on 816 African Americans and 1635 European Americans. 17 Only participants with complete genotype and clinical information for all predictors of interest were included in the analyses. We used data on SCA from followup visit at years 20 (ICA-IMT and CCA-IMT) and 25 (CACS).
The MESA Study
The MESA Study was designed to prospectively evaluate the development and progression of atherosclerotic disease. 19 The selection included individuals from the resident list of adults from the urban areas of the recruiting centers with emphasis on ethnic diversity. The present study included ≤2526 participants of European ancestry, 1611 African Americans, 773 Asian Americans, and 1446 Hispanic Americans from examination year 1 (2000-2001) .
The GENOA Study
The longitudinal GENOA study is one of 4 networks in the National Heart, Lung and Blood Institute Family-Blood Pressure Program and aims to elucidate the genetics of target organ complications of hypertension. 21 GENOA recruited European and African American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. European Americans were recruited from the Rochester, MN, Field Center and African Americans were recruited from the Jackson, MS, Field Center. Current analyses were conducted on CACS measures and genotypes available for 969 European Americans and 535 African Americans.
In all study cohorts, participants with a personal history of CVD defined as myocardial infarction, stroke, coronary angioplasty, or amputation not caused by injury, when applicable, were excluded from the analyses.
Assessment of Subclinical Atherosclerosis
SCA measures were determined in a similar fashion in all studies by carotid ultrasonography intima-media thickness, subcategorized for common and internal carotid (CCA-IMT, ICA-IMT), computed tomography scan for CACS and abdominal aortic calcium score, and ABI for peripheral artery disease. 22, [24] [25] [26] [27] All 5 SCA traits were measured in FHS and MESA participants. ICA-IMT, CCA-IMT, 28 and CACS 29 measurements were available in CARDIA. Evaluation and interpretation of CACS measures in MESA were conducted as published elsewhere. 29, 30 In GENOA, CACS was measured in European Americans with an Imatron C-150 electron beam CT scanner (Imatron Inc., South San Francisco, CA). 31 In GENOA African Americans, CACS was measured with standard scanning protocols developed as part of the National Heart, Lung and Blood Institute's MESA and CARDIA studies. 29 
Genotyping
Genotyping in FHS was conducted using the Affymetrix GeneChip Human Mapping 500K Array supplemented with the Affymetrix 50K array. CARDIA and MESA Studies used the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, CA). 32 GENOA Study used the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 2007) or the Illumina Human 1 mol/L-Duo BeadChip (Illumina, 2010) at the Mayo Clinic, Rochester, MN. Quality control and imputation for missing genotypes were previously detailed 16, [32] [33] [34] for FHS and CARDIA. Complete information on genotyping and imputation quality of MESA and GENOA are available in the Data Supplement.
Ethics Statement
Local Institutional Review Boards approved FHS, CARDIA, MESA, and GENOA study protocols, and all participants provided written informed consent.
Statistical Analysis
The GRS in FHS and CARDIA European Americans was calculated by summing the number of risk alleles (0, 1, or 2) at each locus, weighted by its published effect-size (natural log-transformed). 11 For CARDIA African Americans and for each MESA and GENOA ethnic group, we used an unweighted GRS, calculated by summing the risk alleles across the loci. We used an unweighted GRS for non-European ancestry cohorts because most of the T2D SNPs come from genomewide association studies conducted among people of European ancestry. However, weighting has little effect on the GRS, 35 makes models fit slightly better, but does not change the ranking of individuals from low to high risk. 15, 35 ICA-IMT, CCA-IMT, abdominal aortic calcium score, CACS, fasting insulin, triglycerides, and high-density lipoprotein-cholesterol were log-transformed to reduce skewness. Descriptive data were expressed as mean±SE, if not otherwise indicated. We used multivariable linear regression models for CARDIA and MESA cohorts and similar models in FHS and GENOA, with a random effect accounting for family relatedness to test the association of an additive 62 T2D SNPs GRS ( Table I in For each SCA trait, we applied models adjusted for sex (geneticonly model) and for a comprehensive set of SCA risk factors (full model), as shown in Table II in the Data Supplement. Principal components were included in GENOA and MESA models to control for population stratification in each ethnic group. The fullyadjusted model included sex, age, waist circumference, body mass index, triglycerides, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, fasting insulin, fasting glucose, systolic blood pressure, hypertension/diabetes mellitus, and lipid medication, physical activity, smoking, family history of T2D, and CVD. Systolic blood pressure was excluded in the analysis for ABI because ABI is calculated from systolic blood pressures at ankle and arm.
We also conducted subsidiary analyses of 2 subsets of the 62 T2D SNPs comprising 20 tag-SNPs thought to be associated with β-cell function (GRS β ) or 10 associated with insulin resistance (GRS IR ) 16 in the FHS and CARDIA cohorts to further elucidate possible mechanistic pathways, testing the hypothesis that genetic risk for IR in particular would be associated with SCA.
The rationale behind computing a GRS to account for the cumulative burden of a genetic exposure stands on prior literature. 36, 37 Indeed, using GRS allows to carry out association analyses by treating the genetic exposure as a whole, irrespective of the number of SNPs comprised in the score.
Post hoc power calculations using QUANTO 1.2 software showed that for a sample size of 1835 individuals, we had 80% power to detect association of GRS 62 explaining 0.64% of the variance in SCA traits with type 1 error rate set at P<0.01 (P=0.05 divided by the number of traits (5) analyzed). We had 80% power to detect association of GRS β and GRS IR each explaining 0.73% or more of the variance in SCA traits with type 1 error set at P<0.005 (0.05/[5 traits×2 GRS]).
To replicate the primary FHS analyses in European Americans and to verify whether they might be extended to different ancestral groups, we conducted association analyses of GRS 62 with CACS, ICA-IMT, and CCA-IMT in CARDIA, MESA, and GENOA cohorts separately within each ethnicity. Then association results from each cohort were meta-analyzed using a fixed effect approach, separately for European and African Americans, with a 2-sided P<0.01 as threshold for significance.
All statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, NC) and R 2.9.2 (http://www.r-project.org).
Results
We analyzed ≤7952 European Americans, 2124 Africans Americans, 773 Asian Americans, and 1446 Hispanic Americans from 4 cohort studies. Clinical and anthropometric features and measures of SCA traits are shown for each study cohort in Tables III and IV in the Data Supplement. Overall, study participants were of a wide age and body mass index range. Prevalence of diabetes mellitus and abdominal obesity was much higher in African Americans than in other ethnicities. Participant characteristics within each ethnic group were comparable across all cohorts with the proportion of males and females being equally distributed, except in GENOA African Americans where women comprised 74.2% of the participants. The T2D GRS 62 was approximately normally distributed with a range from 48.3 to 83.3 in European Americans and from 46.8 to 83.2 in African Americans over all cohorts. African Americans in CARDIA had higher mean GRS than European Americans, whereas the opposite was the case in MESA and GENOA cohorts. In MESA Asian and Hispanic Americans, the T2D GRS 62 spanned, respectively, from 48.1 to 73.6 and from 48.5 to 79.6 (Figures I and II in the Data Supplement). GRS β and GRS IR were normally distributed and ranged from 12.2 to 31.9 and from 3.3 to 18.0 in FHS and CARDIA European Americans, respectively, whereas in CARDIA African Americans, the GRS β ranged from 13.2 to 28.4 and the GRS IR ranged from 5.0 to 16.9 ( Figure II in the Data Supplement).
The primary analyses in FHS showed an inverse association between GRS 62 and CCA-IMT (P=0.009, full model), which was not replicated in CARDIA or MESA (Table) European Americans. In the MESA European Americans, there was a significant inverse association between GRS 62 and CACS (P=0.004, full model), which was not replicated in other cohorts (Table) . Lack of a significant association between GRS 62 and SCA was confirmed by meta-analyses of ≤12 983 individuals from 4 cohorts for the available SCA traits, that is, CACS, CCA-IMT, and ICA-IMT ( Figure) .
Supplemental analyses showed that ICA-IMT was negatively associated with GRS β in FHS in the full model (P=0.007; Table V in the Data Supplement), but this finding was not replicated in CARDIA European Americans. The GRS IR was not associated with any SCA trait in any of the models in either the FHS cohort or in either CARDIA ethnic group (Table VI in the Data Supplement).
Discussion
The primary finding of our study was the absence of a significant association between the genetic burden for T2D, based on a 62 SNPs GRS, and a wide set of SCA traits in a large US adult population. Results were consistent for all 4 ancestral groups studied. An inverse association of the GRS 62 with CCA-IMT in FHS was not confirmed in 2 other cohorts either in replication comparisons or meta-analysis. A 10 SNP GRS and a 20 SNP GRS representing variants associated, respectively, with β-cell function or insulin resistance also showed no significant association with SCA.
A wide literature has validated the approach of using a T2D GRS in diverse populations as a robust predictor of T2D, whether alone or considering clinical variables. 16, 17, 35, [38] [39] [40] [41] Prior studies also used the T2D GRS to predict vascular disease, 8, [42] [43] [44] showing that T2D susceptibility variants are able, cumulatively, to predict coronary heart disease events. As single genetic variants only explain a small proportion of the variation in T2D risk, we did not expect individual SNPs to achieve study-wide significance for association with SCA traits, especially with the present sample size. To overcome weak effects of individual variants, we therefore applied the widely used strategy of expressing overall T2D genetic risk burden as a GRS, to test for association with SCA. Indeed, a recent analysis of the cumulative effect of common genetic variation associated with body mass index and fasting insulin loci showed that a higher burden of variants was associated with metabolic syndrome traits, insulin resistance, and coronary heart disease events, but not SCA. 45 Starting with the plausible hypothesis that T2D genetic risk would be associated with SCA, we used a rigorous approach, including conservative correction for multiple trait tests, replication studies in separate cohorts (thereby reducing type 1 error), and meta-analysis of a large sample size (increasing power). We therefore can conclusively state that our formulation of T2D genetic risk is not associated with higher indices of SCA in these cohorts.
These results can be compared with other recent studies. As recently reviewed, 9 the genetic signatures of T2D, coronary heart disease, and glycemic quantitative traits seem to overlap only at chromosomes 2q36.3 and 9p21.3. Notably, a major proportion of fasting insulin-associated loci have shown directionally consistent associations with T2D risk and CVD quantitative risk factors (ie, adverse lipid profile and abdominal adiposity), but none of the glycemic quantitative traits has been directly associated with CVD risk. In this context, Qi et al 8 showed that the genetic risk of T2D, as represented by a 36 T2D SNPs GRS, was associated with an increased risk of CVD in European Americans affected by T2D. Additionally, although Doria et al 46 showed that the effect of genotype at 9p21.3 locus on CVD events was raised only in persons with T2D with poor glycemic control, Rivera et al 47 found that, compared with non-T2D individuals, the genetic variation at 9p21.3 locus was associated with a higher severity of coronary artery disease comorbid with T2D. On the other hand, a recent analysis in the FHS 22 specifically pointing to the genetic variation at candidate 2q36.3-IRS1 locus failed to identify an etiologic link between SCA and T2D.
It might therefore be argued that distinct mechanisms lead T2D and non-T2D subjects to CVD events and that within T2D cases, hyperglycemia might act as permissive environment, leading to the full expression of CVD-risk genetics. These data, together with the null results of our present study, both with our T2D GRS 62 and with the 2 subscores (GRS IR and GRS β ), collectively suggest that in the general population, T2D and CVD are not genetically linked together through SCA, the association of T2D genetics being to date observed only with CVD events but not with early subclinical disease.
Our analysis plan was designed to specifically test the impact of a comprehensive T2D genetic risk burden on SCA risk. We therefore created a basic, purely genetic, model by including as exposure both GRS and sex because sex is 100% genetically determined and is also associated with T2D risk.
Table. Association Between a 62 T2D SNPs Genotype Risk Score (GRS) and Prevalent Subclinical Atherosclerosis Measures in Linear Regression Models of FHS, CARDIA, GENOA,* and MESA Cohorts
Then, we added covariates like age and other confounders/ mediators not completely genetically determined but potentially related to a proatherosclerotic, prodiabetic phenotype. In particular, we did not specifically aim to mechanistically unravel the pathobiology of atherosclerosis. Instead, we adjusted for sex in the genetic-only model to simply address the question of whether the known spectrum of established genetic determinants of T2D (including sex chromosome) is associated with measures of SCA.
Strengths of our study include a validated T2D GRS aligned to the current level of evidence, a detailed characterization of SCA, a comprehensive selection of covariates, and a careful control of type 1 and type 2 error by means of a large sample size from the general population and a multicenter replication strategy in different ethnicities. Additionally, given the strong age-calcification relationship across young adulthood, mid-life, and older ages, 48, 49 the wide range of age among our different cohorts allowed to capture the whole spectrum from early-to late-onset calcification.
However, our approach might have been weakened by multiple interactions among different SNPs within the GRS: several of the component genes in the score may be indeed associated with SCA, but the component score might not be significantly associated if the effect was diluted by the other variants. We did not perform individual SNP tests for association with SCA because individual locus effects were not our main hypothesis and would require a vast sample size to account for the increased type 1 error rate and to identify individual locus effects, the threshold for significance being in that case P<1.6×10 −4 (ie, 0.05/(5 SCA traits) × (62 SNPs)). Furthermore, the 62 genome-wide significant SNPs we used explained only a fraction (around 10%) of the total T2D phenotypic variance in other studies 50 and did not represent actual functional variants that have yet to be discovered. We also acknowledge that the exclusion of CVD individuals may have resulted in a population enriched for protective factors, especially among those with higher T2D GRS, which would explain the borderline negative association of the GRS 62 with CCA-IMT in FHS and CACS in MESA European Americans. However, in sensitivity analyses conducted in FHS and CARDIA, the T2D GRS 62 allele distribution was comparable between people with positive CVD history and the population actually analyzed (data not shown). Hence, for consistency with our main focus on SCA, we excluded individuals with clinical CVD. The relatively younger age of CARDIA participants offers another possible limitation; however, it is well known that SCA begins to develop in Westernized populations in early youth. 51, 52 Further, associations in CARDIA were similar to those in the other cohorts we studied. Finally, although we could confidently use the GRS to depict the T2D genetic risk for European and Mexican Americans and therefore reasonably claim robustness of our results, our GRS was not best tailored to African or Asian Americans. However, we have shown in several prior studies that T2D GRS based on SNPs found in European ancestry samples do predict T2D in African American samples, even accounting for clinical risk factors. 16, 17, 53 Our results have several implications and point to future directions. We provided compelling evidence that the genetic burden of T2D risk as represented by our GRS 62 formulation was not associated with SCA. This suggests that T2D and SCA have separate genetic structures and that no large common variant genetic soil 10 underlies both T2D and CVD. However, it is possible that more complex formulation of T2D genetic risk might be associated with SCA.
T2D and SCA are linked clinically 1, 8 and the prevalence of CVD events and the burden of CVD risk factors are higher in T2D patients. Furthermore, there is evidence that screening for SCA in asymptomatic individuals at intermediate CVD risk improves the predictability of the occurrence of CVD over and above established CVD risk factors. 54 Incorporating genetic information into disease prediction models would further improve the ability to capture people with higher CVD risk at a preclinical stage. However, current polygenic scores do not remarkably outperform clinical models, 15 and functional interrogation of T2D and CVD genetics is necessary to further optimize polygenic risk prediction of either T2D or CVD or both. Therefore, despite our understanding of the genetic signature of complex traits is steadily increasing, new approaches incorporating functional, structural, and regulatory annotation 55 into disease prediction are needed to untangle the missing link, if any, between T2D and CVD at a genetic level.
In conclusion, common polygenic T2D risk variation, as incorporated in a comprehensive and validated GRS, was not associated with any of 5 measures of SCA. Our study suggests that the biological and genetic relationships among T2D, CVD, and SCA are probably more complex than expected. Further mechanistic investigations are needed to explore whether shared or distinct vascular disease mechanisms related to T2D might be in play. Therefore, given the global burden of T2D and CVD in the era of precision medicine and patient-oriented healthcare, it is timely to achieve a deeper understanding about the genetic determinants of T2D, CVD, and intermediate risk traits to improve risk prediction and the ability to discover newly targeted therapeutic molecules. 
Sources of Funding
Disclosures
The FHS, CARDIA, MESA, and GENOA authors have no conflict of interest to disclose. J.B. Meigs serves as consultant to Quest Diagnostics. The other authors report no conflicts.
